📰 Future Royalties News
Future Royalties News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Future Royalties. Real-time updates on events, politics, business and more.
April 25, 2024
Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for...
May 3, 2023
- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival... | May 3, 2023
November 9, 2022
Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous
November 9, 2022
Investegate announcements from Minerva Neurosciences, Inc, Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
August 9, 2022
Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022WALTHAM, Mass., Aug. 09, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused
August 9, 2022
Investegate announcements from Minerva Neurosciences, Inc, Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
May 12, 2022
SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics
May 4, 2022
Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage
August 12, 2021
SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics
May 11, 2021
Aptevo Therapeutics Reports First Quarter 2021 Financial Results Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today rep...